Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Genzyme Japan Launches Oral Gaucher’s Disease Treatment Cerdelga
September 2, 2015
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Baxalta Japan Aims for 6-8% Annual Growth by 2020: President Kawamoto
September 1, 2015
- Merck Serono Initiates Voluntary Recall of Ovulation Inducer Serophene Due to Deviation from In-House Specifications
September 1, 2015
- GSK Paid 9.3 Billion Yen to Physicians, Medical Institutions in 2014
August 31, 2015
- Towa Raises Production Target to 14 Billion Tablets: Pres. Yoshida
August 31, 2015
- Hisamitsu Starts PII Study of Analgesic Transdermal Patch for Lower Back Pain in Japan
August 31, 2015
- Seikagaku to Cease Development of Rheumatoid Arthritis Treatment Licensed from Can-Fite
August 31, 2015
- Takeda Inks Deal with Nanotherapeutics to Expand Vaccine Technology Rights
August 28, 2015
- MTPC Chief Hints at No Major Merger, Plans Departure from Go-It-Alone Policy
August 28, 2015
- Jardiance Reduces Cardiovascular Risks: BI, Lilly
August 28, 2015
- Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan
August 27, 2015
- Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
August 27, 2015
- Tresiba Approved for Pediatric Use: Novo Nordisk
August 27, 2015
- ASKA to Launch Authorized Generics of Takeda’s Unisia
August 26, 2015
- Artist Approved for Tachycardiac Atrial Fibrillation: Daiichi Sankyo
August 26, 2015
- Cravit Approved for Pulmonary Tuberculosis: Daiichi Sankyo
August 26, 2015
- Ono, Novartis Gain Approval of One-Step Titration Regimen for AD Drug Rivastigmine
August 26, 2015
- Chugai Files CellCept for Lupus Nephritis Based on Information in Public Domain
August 26, 2015
- Novo Nordisk to Roll Out NovoThirteen on Aug. 27
August 25, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…